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Background:  Renal sympathetic denervation (RSD) represents an effective treatment option for patients with resistant arterial hypertension. 
Chronic vascular inflammation and remodeling are associated with the pathogenesis of hypertension, contributing to progressive vascular damage 
and atherosclerosis. In the present study we aimed to evaluate the influence of RSD on vascular inflammation and remodeling by determining serum 
levels of interleukin-6 (IL-6), high-sensitive C-reactive protein (hsCRP), tumor necrosis factor-α (TNF-α), and matrix metalloproteinases-9 (MMP-9) 
in resistant hypertensive patients.
methods:  A total of 55 consecutive patients (age: 67.9±9.6 yrs) undergoing RSD were included in this study. A therapeutic response was defined 
as a systolic blood pressure reduction of > 10 mmHg in the office blood pressure measurement 6 months after RSD. Venous serum samples for 
measurement of hsCRP, TNF-α, IL-6, and MMP-9 were collected prior to and 6 months after RSD.
Results:  A significant reduction in the systolic office blood pressure of 26.4 mmHg (baseline RRsys: 167.4 mmHg [SD: 11.3], <0.001) was 
documented 6 months after RSD. A significant reduction in the levels of pro-inflammatory cytokines hsCRP (Baseline: 3.6 mg/dl [IQR: 1.9;6.3] vs. 
Follow-Up: 1.7 mg/dl [IQR:0.9;2.4], p<0.001) and IL-6 (Baseline: 4.04 pg/ml [IQR:2.7;6.5] vs. Follow-Up: 2.2 pg/ml [IQR:1.6:3.2], p<0.001) and a 
significant increase in the levels of TNF-α (Baseline: 22.8 pg/ml [IQR:13.9;30.9] vs. Follow-Up: 29.5 pg/ml [IQR: 22.9; 37.8], p<0.01) and MMP-9 
(Baseline: 425.2 ng/ml [IQR: 309.3; 573.4] vs. Follow-Up: 574.1 ng/ml [IQR: 463.3; 860.2], p=0.02) were observed after 6 months of follow-up.
conclusion:  In addition to the effective blood pressure reduction in response to RSD, this study showed for the first time a positive effect of 
RSD on biomarkers reflecting vascular inflammation and remodeling as well as on the neuroendocrine system. Therefore, these results suggest a 
prognostic benefit of RSD in high-risk patients for endothelial dysfunction and atherosclerosis as well as end-organ damage.
